DBK Pharma is preparing to re-list its shares on the Egyptian Stock Exchange (EGX) by end of November 2016, after it had been delisted in December 2015 as it failed to float 35% of its shares.  The company is currently undertaking the necessary steps in preparation of the listing in November,  after it had hired the legal and financial advisors, according to a reliable source speaking to Al Borsa. DBK pharma is planning to use the proceeds to expand production capacities, as well as entering into veterinary vaccines production, for which local production would be favourable due to FX issues. DBK Pharmaceutical is an integrated pharmaceutical company engaged in the development, manufacturing, marketing and sales of pharmaceutical, herbal brands, food supplements, cosmetics and veterinary products. DBK Pharma reported a net profit of EGP21mn in 1H16, and currently has a paid in capital of EGP149mn. (Al Borsa, company website)